HC Wainwright Brokers Lower Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Research analysts at HC Wainwright cut their Q2 2026 earnings estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, December 2nd. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will earn ($1.05) per share for the quarter, down from their prior estimate of ($1.01). HC Wainwright currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.38) EPS, FY2026 earnings at ($2.13) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.25) EPS, Q4 2027 earnings at ($0.37) EPS, FY2027 earnings at ($3.95) EPS, FY2028 earnings at ($3.39) EPS, FY2029 earnings at ($1.33) EPS and FY2030 earnings at $2.29 EPS.

A number of other brokerages have also issued reports on ARWR. Royal Bank Of Canada increased their price target on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Bank of America boosted their price objective on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 26th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday. Finally, The Goldman Sachs Group upped their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.33.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $65.07 on Thursday. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $66.23. The firm has a market capitalization of $8.84 billion, a PE ratio of -813.27 and a beta of 1.28. The company’s 50 day simple moving average is $40.78 and its 200 day simple moving average is $26.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after acquiring an additional 2,774,933 shares in the last quarter. Marshall Wace LLP raised its stake in Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after purchasing an additional 2,017,489 shares in the last quarter. Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth $30,414,000. Finally, Vanguard Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after buying an additional 1,018,273 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insiders Place Their Bets

In other news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares of the company’s stock, valued at $7,424,270. This represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mauro Ferrari sold 8,750 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $56.39, for a total value of $493,412.50. Following the completion of the transaction, the director owned 68,764 shares of the company’s stock, valued at $3,877,601.96. This trade represents a 11.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,750 shares of company stock worth $1,643,413 over the last ninety days. 4.30% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.